Merrida A Childress
Affiliations: | 2019- | Department of Medicine | Vanderbilt University, Nashville, TN |
Google:
"Merrida Childress"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Moyo TK, Kishtagari A, Villaume M, et al. (2023) PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in patients with Myelofibrosis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Fischer MA, Song Y, Arrate MP, et al. (2022) Selective inhibition of MCL1 overcomes venetoclax-resistance in a murine model of myelodysplastic syndromes. Haematologica |
| Ramsey HE, Stengel K, Pino JC, et al. (2021) Selective Inhibition of JAK1 Primes STAT5-Driven Human Leukemia Cells for ATRA-Induced Differentiation. Targeted Oncology |
| Villaume MT, Arrate MP, Ramsey HE, et al. (2021) The delta isoform of PI3K predominates in chronic myelomonocytic leukemia and can be targeted effectively with umbralisib and ruxolitinib. Experimental Hematology |
| Ramsey HE, Greenwood DL, Zhang S, et al. (2020) BET inhibition enhances the antileukemic activity of low-dose Venetoclax in acute myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Strickland SA, Podoltsev NA, Mohan SR, et al. (2019) The VITAL Trial: Phase II Trial of Vosaroxin and Infusional Cytarabine for Frontline Treatment of acute Myeloid Leukemia Blood. 134: 180-180 |
| Fischer MA, Arrate M, Childress MA, et al. (2019) Variable Response to BCL2 Inhibition in MDS Is Enhanced across MDS Subtypes with Synergistic Combination of BCL2+MCL1 Inhibition Blood. 134: 2982-2982 |
| Childress MA, Himmelberg SM, Chen H, et al. (2018) ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties. Molecular Cancer Research : McR |
| Johnson DB, Childress MA, Chalmers ZR, et al. (2017) BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy. Pigment Cell & Melanoma Research |